leadf
logo-loader
RNS
viewAllergan

D E Shaw & Co LP - Form 8.3 - Allergan Plc

RNS Number : 5314M
D E Shaw & Co LP
11 May 2020
 

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

D. E. Shaw & Co., L.P.

Company dealt in

Allergan plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.0001 ordinary shares

Date of dealing

May 08, 2020

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

US$0.0001 ordinary shares

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

  779,249                        (0.23%)

1,918             (0.00%)                    

(2) Derivatives (other than options)

 2,887,118                       (0.87%)

 

(3) Options and agreements to purchase/sell

 

32,300           (0.00%)

Total

 3,666,367                      (1.11%)

34,218           (0.01%)

             

 

 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

 

Ap20

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Sale

100

USD 191.87

Sale

100

USD 191.93

Sale

100

USD 192.13

Sale

200

USD 192.35

Sale

100

USD 192.43

Sale

100

USD 192.55

Sale

100

USD 192.69

Sale

100

USD 192.73

Sale

200

USD 192.76

Sale

100

USD 192.88

Purchase

100

USD 192.72

 

(b)      Derivatives transactions (other than options transactions)

 

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

(ii)      Exercising

 

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

 

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

 

Ap21

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            YES

 

Date of disclosure

May 11, 2020

Contact name

Kevin Krist (Compliance Department)

Telephone number

+44 (0) 20 7409 4420

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                                                                                                                     Ap23

 

SUPPLEMENTAL FORM 8

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

 

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

OPEN POSITIONS (Note 1)

 

Product name, e.g. call option

Written, or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Put Option

Purchased

5,000

USD 110

American

20210115

Put Option

Purchased

10,000

USD 120

American

20210115

Put Option

Purchased

10,000

USD 135

American

20210115

Put Option

Purchased

7,300

USD 140

American

20210115

 

 

 

Notes

 

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full 

         details of any existing agreements to purchase or to sell must also be given on this form.

 

2.          For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISEEADSFFSNEEFA

Quick facts: Allergan

Price: -

Market: NYSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read